Home › NCT07075471

MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Real-World Patient Experience of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor (MOVE)

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Diagnosis of TGCT according to medical records
2. Prescribed vimseltinib per the approved label requirements, OR The decision to receive vimseltinib has been made but treatment has not yet been initiated.
3. Has provided informed consent and medical records release

Exclusion Criteria:

1\. Participant is active in an interventional clinical trial of vimseltinib

About the study

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.

This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Sponsor: Deciphera Pharmaceuticals, LLC · Participants: 100 · Started: Sep 3, 2025

Contact the study team

• Clinical Team · Phone: 888-724-3274

Official record on ClinicalTrials.gov — NCT07075471

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.